Cited by 18Extracellular vesicles in diseaseCaveolin-1 and cellular processesGlioma Diagnosis and Treatment

A Novel Localization in Human Large Extracellular Vesicles for the EGF-CFC Founder Member CRIPTO and Its Biological and Therapeutic Implications

Open access
Mantile, Francesca, Kisovec, Matic, Adamo, Giorgia, Romancino, Daniele P., Hočevar, Matej, Božič, Darja, Bedina Zavec, Apolonija, Podobnik, Marjetka +5 more·2022·Cancers

Abstract

Tumor growth and metastasis strongly rely on cell-cell communication. One of the mechanisms by which tumor cells communicate involves the release and uptake of lipid membrane encapsulated particles full of bioactive molecules, called extracellular vesicles (EVs). EV exchange between cancer cells may induce phenotype changes in the recipient cells. Our work investigated the effect of EVs released by teratocarcinoma cells on glioblastoma (GBM) cells. EVs were isolated by differential centrifugation and analyzed through Western blot, nanoparticle tracking analysis, and electron microscopy. The effect of large EVs on GBM cells was tested through cell migration, proliferation, and drug-sensitivity assays, and resulted in a specific impairment in cell migration with no effects on proliferation and drug-sensitivity. Noticeably, we found the presence of the EGF-CFC founder member CRIPTO on both small and large EVs, in the latter case implicated in the EV-mediated negative regulation of GBM cell migration. Our data let us propose a novel route and function for CRIPTO during tumorigenesis, highlighting a complex scenario regulating its effect, and paving the way to novel strategies to control cell migration, to ultimately improve the prognosis and quality of life of GBM patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers14153700

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The optimized protocol uses silicone culture inserts to enhance wound homogeneity and reproducibility.

    “The protocol incorporates the use of silicone culture inserts to enhance wound homogeneity and reproducibility”

    From Optimized Wound Healing Assay to Study Extracellular Vesicle-Driven Glioblastoma Cell Migration (2026) · cites this paper as [43]

    Section 2.9 (Wound Healing Assay; page unavailable) says the researchers used Ibidi inserts in a wound-healing assay. It does not identify the inserts as silicone or say they were used to improve wound homogeneity or reproducibility. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Extracellular vesicle isolation and characterization were performed according to MISEV 2018 and 2023.

    “EV isolation and characterization were performed according to MISEV 2018 and 2023 [49,50], as previously reported [43].”

    From Optimized Wound Healing Assay to Study Extracellular Vesicle-Driven Glioblastoma Cell Migration (2026) · cites this paper as [43]

    Materials and Methods §2.2 describes EV isolation by differential centrifugation, and §2.11 says the study followed MISEV2018. Results §3.1 describes EV characterization using markers recommended by MISEV2018. The source does not support the attributed reference to MISEV 2023. (LLM, conf=0.90)

    Experimental — accuracy not yet measured
  • The core methodology was first established in a previous study on the effect of NTERA2 teratocarcinoma-derived extracellular vesicles on U87 glioblastoma cell migration.

    “The core methodology was first established in our previous study on the effect of NTERA2 teratocarcinoma-derived EVs on the U87 GB cell migration [43]”
  • Continuous Mitomycin C incubation inhibits cell proliferation.

    “continuous Mitomycin C incubation to inhibit cell proliferation without inducing”
  • The identity of the extracellular vesicles was confirmed by showing they possessed specific positive markers CD63 and HSP70, while lacking the negative marker Calnexin.

    “The identity of the EVs was confirmed by showing they possessed specific positive markers, such as the CD63 membrane-bound marker and the HSP70 luminal marker, while lacking negative markers specific of intracellular compartments (Calnexin) [43].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 84 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Mantile, F., Kisovec, M., Adamo, G., Romancino, D. P., Hočevar, M., Božič, D., Bedina Zavec, A., Podobnik, M., Stoppelli, M. P., Kisslinger, A., Bongiovanni, A., Kralj-Iglič, V., & Liguori, G. L.
Affiliations
  • Institute of Genetics and Biophysics (IT)
  • National Institute of Chemistry (SI)
  • Institute for Biomedical Research and Innovation (IT)
  • Institute of Metals and Technology (SI)
  • University of Ljubljana (SI)
  • Department of Molecular Biology and Nanobiotechnology, National Institute of Chemistry, SI-1000 Ljubljana, Slovenia
  • Institute for Experimental Endocrinology and Oncology (IT)
  • Faculty of Health Sciences, University of Ljubljana, SI-1000 Ljubljana, Slovenia
Corresponding author
Liguori, Giovanna L.
Venue
Cancers
Publisher
MDPI AG
Published
2022-07-29
Volume
14
Issue
15
Pages
3700
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4289111711
Cited by
18
References
84
Citations by year
2026: 3 · 2025: 4 · 2024: 5 · 2023: 5 · 2022: 1
FWCI
1.22
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Regione Campania (PO FESR 2014–2020 SATIN, 801338, P3-0388, J1-9162, J3-3066, P2-0132, P1-0391)
  • VES4US project (PO FESR 2014–2020 SATIN, 801338, P3-0388, J1-9162, J3-3066, P2-0132, P1-0391)
  • Slovenian Research Agency ARRS (PO FESR 2014–2020 SATIN, 801338, P3-0388, J1-9162, J3-3066, P2-0132, P1-0391)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Caveolin-1 and cellular processes
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
Keywords
extracellular vesicles, Cripto, glioblastoma, teratocarcinoma cells, cell migration, tumor growth and metastasis, cell proliferation, drug sensitivity, carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review